http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
-
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Karyopharm Therapeutics (KPTI) Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives
-
Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives
-
Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference
-
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SV
-
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Karyopharm to Participate at Upcoming Investor Conferences
-
Karyopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgr
-
Karyopharm Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (ASH)
-
Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
-
Karyopharm Therapeutics (KPTI) Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor
-
Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory M
-
Karyopharm to Report Third Quarter 2023 Financial Results on November 2, 2023
-
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Karyopharm to Present Selinexor Data at the 2023 International Myeloma Society Annual Meeting and European Society of Gynaecological Oncology 2023 Annual Meetings
-
Karyopharm to Participate at Upcoming Investor Conferences
-
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Karyopharm Therapeutics (KPTI) Appoints Zhen Su to its Board
-
Karyopharm Appoints Zhen Su, MD, MBA to its Board of Directors
-
Karyopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
-
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Karyopharm to Report Second Quarter 2023 Financial Results on August 2, 2023
-
Karyopharm Therapeutics (KPTI) Presentation of Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer
-
Karyopharm Announces Presentation of Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer
-
Karyopharm Announces Updated Exploratory Subgroup Analysis from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer to be Presented at ASCO Plenary Series on July 25t
-
Karyopharm Therapeutics (KPTI) Granted FDA Fast Track Designation for Selinexor
-
Karyopharm Receives FDA Fast Track Designation for Selinexor for the Treatment of Myelofibrosis
-
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Karyopharm Therapeutics (KPTI) Initiates Pivotal Phase 3 Study of XPO1 Inhibitor Selinexor and Ruxolitinib in JAK Inhibitor (JAKi) Naïve Myelofibrosis
-
Karyopharm Initiates Pivotal Phase 3 Study of XPO1 Inhibitor Selinexor and Ruxolitinib in JAK Inhibitor (JAKi) Naïve Myelofibrosis
-
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Karyopharm to Participate at the Jefferies Healthcare Conference
-
Karyopharm to Present New Selinexor Data at the 2023 American Society of Clinical Oncology and European Hematology Association Annual Meetings
-
Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
-
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Karyopharm to Report First Quarter 2023 Financial Results on May 4, 2023
-
Karyopharm Therapeutics (KPTI) Presents Updated Phase 1 Selinexor Data
-
Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at AACR 2023
-
Karyopharm To Present Data from Phase 1 Study of Selinexor in Patients with Treatment-Naïve Myelofibrosis at AACR and to Host Investor Webcast on April 18th
-
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Karyopharm Announces Updated Selinexor Data in Patients with Treatment-Naïve Myelofibrosis to be Presented at AACR 2023
-
Karyopharm to Participate at Barclays Global Healthcare Conference
-
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO® (selinexor) in Combination with Bortezomib and Dexam
-
Karyopharm (KPTI) and Menarini Granted Full Marketing Authorization for NEXPOVIO in Combination with Bortezomib and Dexamethasone in the UK
-
Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO® (selinexor) in Combination with Bortezomib and Dexam
-
Karyopharm Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress
-
Karyopharm to Present at SVB Securities Global Biopharma Conference
